- Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech company
- Plans to build a pipeline of ADCs directed at novel cancer targets and bring lead uPARAP/Endo180 program through clinical development to proof of concept in patients
Copenhagen, Denmark, 29 April 2021 – Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The investment was led by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was initially incubated and funded at the BioInnovation Institute (BII).